SAN
DIEGO, May 23, 2023 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene
therapy company advancing a new class of treatments for patients
with cancer and rare diseases, today announced that the Company's
President of Gene Therapy, Brent
Warner, will participate in a virtual fireside chat at the
Stifel 2023 Tailoring Genes: Genetic Medicines Day on Tuesday, May 30, 2023 at 12:00pm PT | 03:00pm
ET.
A live webcast of the fireside chat will be available on the
Investors & Media Section of Poseida's website,
www.poseida.com. A replay of the webcast will be available for
approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics
is a clinical-stage biopharmaceutical company advancing
differentiated cell and gene therapies with the capacity to cure
certain cancers and rare diseases. The Company's pipeline includes
allogeneic CAR-T cell therapy product candidates for both solid and
liquid tumors as well as in vivo gene therapy product candidates
that address patient populations with high unmet medical need. The
Company's approach to cell and gene therapies is based on its
proprietary genetic editing platforms, including its non-viral
piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific
Gene Editing System and nanoparticle and hybrid gene delivery
technologies. The Company has formed global strategic
collaborations with Roche and Takeda to unlock the promise of cell
and gene therapies for patients. Learn more at www.poseida.com and
connect with Poseida on Twitter and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-stifel-2023-tailoring-genes-genetic-medicines-day-301829940.html
SOURCE Poseida Therapeutics, Inc.